Smoothened-Activating Lipids Drive Resistance to CDK4/6 Inhibition in Hedgehog-Associated Medulloblastoma
Oncology; Neurosciences & Neurology; Clinical Neurology
Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup A; Kaur P; Tong P; Li A; Xu L; Reiter J; Raleigh D
Neuro-oncology
2020
2020-11
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/" target="_blank" rel="noreferrer noopener"></a>
Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
Humans; Male; Female; Child; Child Preschool; Bacterial Infections/epidemiology/therapy; bloodstream infections; CLABSI; Databases Factual; hematology; mucosal barrier injury; Neoplasms/epidemiology/therapy; Neutropenia/epidemiology/therapy; oncology; pediatric; transplant; Mucous Membrane/injuries
BACKGROUND: Single-center reports of central line-associated bloodstream infection (CLABSI) and the subcategory of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) in pediatric hematology oncology transplant (PHO) patients have focused on the inpatient setting. Characterization of MBI-LCBI across PHO centers and management settings (inpatient and ambulatory) is urgently needed to inform surveillance and prevention strategies. METHODS: Prospectively collected data from August 1, 2013, to December 31, 2015, on CLABSI (including MBI-LCBI) from a US PHO multicenter quality improvement network database was analyzed. CDC National Healthcare Safety Network definitions were applied for inpatient events and adapted for ambulatory events. RESULTS: Thirty-five PHO centers reported 401 ambulatory and 416 inpatient MBI-LCBI events. Ambulatory and inpatient MBI-LCBI rates were 0.085 and 1.01 per 1000 line days, respectively. Fifty-three percent of inpatient CLABSIs were MBI-LCBIs versus 32% in the ambulatory setting (P < 0.01). Neutropenia was the most common criterion defining MBI-LCBI in both settings, being present in ≥90% of events. The most common organisms isolated in MBI-LCBI events were Escherichia coli (in 28% of events), Klebsiella spp. (23%), and viridans streptococci (12%) in the ambulatory setting and viridans streptococci (in 29% of events), E. coli (14%), and Klebsiella spp. (14%) in the inpatient setting. CONCLUSION: In this largest study of PHO MBI-LCBI inpatient events and the first such study in the ambulatory setting, the burden of MBI-LCBI across the continuum of care of PHO patients was substantial. These data should raise awareness of MBI-LCBI among healthcare providers for PHO patients, help benchmarking across centers, and help inform prevention and treatment strategies.
Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH
Pediatric Blood & Cancer
2020
2020-08
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1002/pbc.28234" target="_blank" rel="noreferrer noopener">10.1002/pbc.28234</a>
Contributing Roles of CYP2E1 and Other Cytochrome P450 Isoforms in Alcohol-Related Tissue Injury and Carcinogenesis
inflammation; Oxidative stress; Cancer; CYP2E1; Cell Biology; Oncology; Alcohol; Acetaldehyde; Biomedical and Life Sciences; Cancer Research; DNA mutation; Life Sciences
The purpose of this review is to briefly summarize the roles of alcohol (ethanol) and related compounds in promoting cancer and inflammatory injury in many tissues. Long-term chronic heavy alcohol exposure is known to increase the chances of inflammation, oxidative DNA damage, and cancer development in many organs. The rates of alcohol-mediated organ damage and cancer risks are significantly elevated in the presence of co-morbidity factors such as poor nutrition, unhealthy diets, smoking, infection with bacteria or viruses, and exposure to pro-carcinogens. Chronic ingestion of alcohol and its metabolite acetaldehyde may initiate and/or promote the development of cancer in the liver, oral cavity, esophagus, stomach, gastrointestinal tract, pancreas, prostate, and female breast. In this chapter, we summarize the important roles of ethanol/acetaldehyde in promoting inflammatory injury and carcinogenesis in several tissues. We also review the updated roles of the ethanol-inducible cytochrome P450-2E1 (CYP2E1) and other cytochrome P450 isozymes in the metabolism of various potentially toxic substrates, and consequent toxicities, including carcinogenesis in different tissues. We also briefly describe the potential implications of endogenous ethanol produced by gut bacteria, as frequently observed in the experimental models and patients of nonalcoholic fatty liver disease, in promoting DNA mutation and cancer development in the liver and other tissues, including the gastrointestinal tract.
Byoung-Joon Song; Mohamed A Abdelmegeed; Young-Eun Cho; Mohammed Akbar; Johng S Rhim; Min-Kyung Song; James P Hardwick
Human Cell Transformation : Advances In Cell Models For The Study Of Cancer And Aging
2019
1905-07
Journal Article
<a href="http://doi.org/10.1007/978-3-030-22254-3_6" target="_blank" rel="noreferrer noopener">10.1007/978-3-030-22254-3_6</a>
Red Tattoo Reactions - Treatment With The Carbon-dioxide Laser
Dermatology; Oncology; Surgery
Kyanko M E; Pontasch M J; Brodell R T
Journal of Dermatologic Surgery and Oncology
1989
1989-06
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1111/j.1524-4725.1989.tb03604.x" target="_blank" rel="noreferrer noopener">10.1111/j.1524-4725.1989.tb03604.x</a>
Toxicity Associated With High-dose Cytosine Arabinoside And Total Body Irradiation As Conditioning For Allogeneic Bone Marrow Transplantation
acute lymphoblastic-leukemia; adults; allogeneic; Biophysics; children; cyclophosphamide; cytosine; hematologic; Hematology; Immunology; lymphoma; malignancies; Oncology; preparative regimen; remission; survival; therapy; total body irradiation; toxicity; transplantation; transplantation
Seventy-three patients with hematological cancers undergoing allogeneic bone marrow transplantation (BMT) were evaluated for event-free survival (EFS) and toxicity, All received 36 g/m(2) cytosine arabinoside (HDA) and 1200 cGy fractionated total body irradiation (TBI). We assessed the association of EFS and toxicities with the following risk factors: age, gender, diagnosis, initial relapse risk and patient-donor histocompatibility. The EFS probability is 33% at 800 days post-BMT, Twenty-six patients (36%) died of toxicity within 100 days and 14 (19%) have relapsed, EFS was inversely associated with age (P < 0.0001) and initial relapse risk (P = 0.007), The risk of pulmonary (P = 0.023) and hepatic toxicity (P = 0.011) increased with age, Diagnosis other than acute lymphoblastic leukemia (ALL) was a risk factor (P = 0.015) for graft-versushost disease (GVHD); and fewer ALL patients died from toxicity (P = 0.014), The probability of sepsis within 100 days post-BMT correlated (P = 0.007) with initial relapse risk. We conclude: (1) the lower EFS and greater pulmonary and hepatic toxicity associated with increasing age indicate a need for less toxic regimens that maintain high antileukemic efficacy for older patients; (2) the high GVHD and sepsis rates seen in certain categories of patients indicate a need for careful definition of eligibility criteria for this still highly toxic treatment.
Kumar M; Saleh A; Rao P V; Ochoa S; Meyers L; Miller A; GrahamPole J
Bone Marrow Transplantation
1997
1997-06
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1038/sj.bmt.1700797" target="_blank" rel="noreferrer noopener">10.1038/sj.bmt.1700797</a>
Human-alpha-2-macroglobulin - A Major Serum Factor Cyto-toxic For Tumor-cells
Oncology
Koo P H
Cancer Letters
1983
1983
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/0304-3835(83)90064-2" target="_blank" rel="noreferrer noopener">10.1016/0304-3835(83)90064-2</a>
Growth And Antigenic Properties Of A Spontaneously Regressing Subline Of Leukemia-l1210
Oncology
Koo P H
European Journal of Cancer & Clinical Oncology
1982
1982
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/0277-5379(82)90142-0" target="_blank" rel="noreferrer noopener">10.1016/0277-5379(82)90142-0</a>
Radiographically Guided Shave Margins May Reduce Lumpectomy Re-excision Rates: A Single-surgeon Experience
Oncology; Surgery
Iyer P; Marko A; Jadeja V; Pratt D
Annals of Surgical Oncology
2016
2016-04
Journal Article or Conference Abstract Publication
n/a
Breast-cancer - Factors Associated With Stage At Diagnosis In Black-and-white Women
american-college; body size; national survey; Oncology; patient characteristics; positive axillary nodes; progesterone-receptor; racial-differences; self-examination; socioeconomic-status; united-states
Background: Numerous studies have reported differences in cancer staging at diagnosis and in survival between Black and White patients with breast cancer. Utilizing data obtained from the National Cancer Institute's (NCI's) Black/White Cancer Survival Study for the period 1985-1986, a new study is presented here that systematically examines multiple explanatory factors (e.g., lack of mammograms) associated with these cancer-staging differences. Purpose: We evaluated within a single study the relationship of selected demographic, lifestyle, antecedent medical experiences, and health care acces s factors to cancer staging at diagnosis in Black and White breast cancer patients. Methods: Data utilized in this population-based cohort study of 1222 eligible women (649 Black and 573 White) newly diagnosed for the period 1985-1986 with histologically confirmed primary breast cancer were obtained from the NCI's Black/White Cancer Survival Study. Sources of data included abstracts of hospital medical records, central review of histology slides by a study consultant pathologist, and patient interviews obtained from three metropolitan areas: Atlanta, New Orleans, and San Francisco-Oakland. Within each area, 70% of all Black incident cases were randomly selected, and a sample of White cases, frequency matched by age groups (20-49 years, 50-64 years, and 65-79 years), was selected for comparison. Stage of breast cancer at diagnosis was classified according to the international tumor-lymph node-metastases (TNM) system. Statistical models utilized in this study included the log-linear and polychotomous logistic regression with multiple predictor variables. Results: Factors associated with cancer staging were differentially expressed in Blacks and Whites. Indicators of access to health care, a lack of mammograms, and an increased body mass index significantly (P<.02) contributed to stage differences in Blacks, whereas income was marginally associated (P = .06) with stage for Whites only. Nuclear grade, having a breast examination by a physician, and a history of patient delay explained approximately 50% of the excess risk for stage III-IV Cancer versus stage I-II(N0) cancer among Blacks compared with Whites (odds ratio- reduction from 2.19 to 1.68). Conclusion: These findings suggest that no single factor or group of factors can explain more than half of the race-stage differences noted in this study with respect to Black and White breast cancer patients.
Hunter C P; Redmond C K; Chen V W; Austin D F; Greenberg R S; Correa P; Muss H B; Forman M R; Wesley M N; Blacklow R S; Kurman R J; Dignam J J; Edwards B K; Shapiro S
Journal of the National Cancer Institute
1993
1993-07
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1093/jnci/85.14.1129" target="_blank" rel="noreferrer noopener">10.1093/jnci/85.14.1129</a>
Cervical Cancer In Pregnancy
Obstetrics & Gynecology; Oncology
Hopkins M P; Lavin J P
Gynecologic Oncology
1996
1996-12
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1006/gyno.1996.0324" target="_blank" rel="noreferrer noopener">10.1006/gyno.1996.0324</a>
George W. Morley, Md (1923-2005) - In Memoriam
Obstetrics & Gynecology; Oncology
Hopkins M P; Gallup D G; Reynolds R K
Gynecologic Oncology
2006
2006-02
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.ygyno.2005.12.008" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2005.12.008</a>
Re: Letter By Manjunath
Obstetrics & Gynecology; Oncology
Hopkins M P
Gynecologic Oncology
2008
2008-06
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.ygyno.2008.02.029" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2008.02.029</a>
Evaluation Of Appropriate Short-term Mammographic Surveillance In Patients Who Undergo Breast-conserving Surgery (bcs)
cancer; carcinoma; conservative surgery; follow-up; irradiation; local recurrence; lumpectomy; Oncology; radiation-therapy; radiotherapy; stage-i; Surgery
Mammography is an important surveillance tool for detecting ipsilateral breast tumor recurrence (IBTR) after BCS. Although IBTR is rare in the first 2 years, various organizations have established protocols for postoperative mammographic surveillance. Currently there is no consensus on the optimal interval for imaging evaluation of patients following BCS. We conducted a retrospective review of patients who underwent BCS at Aultman Hospital between 1/06 and 12/08. To be included in the study, patients had to be diagnosed with invasive primary breast carcinoma or ductal carcinoma in situ (DCIS), treated with BCS (with or without postoperative breast radiation), and have had at least one postoperative surveillance mammogram at our Breast Care Center. Our mammographic surveillance protocol for patients undergoing BCS consists of ipsilateral mammograms (affected side) around 6 and 18 months and bilateral mammograms around 12 and 24 months. All mammograms that were Breast Imaging-Reporting and Data System (BIRADS) 0 or 4 were reviewed by a single radiologist (T.B.P.). A total of 375 patients constituted the core group for this study. Each interval mammographic screening (6- and 18-month mammograms) resulted in additional imaging in 3-4 % of patients. There was a very low yield for identifying IBTR: 1/266 (0.4 %) for the 5-10-month postoperative mammogram and 1/286 (0.3 %) for the 16-21-month postoperative mammogram. Based on our data and the low expected yield of IBTR in the first 2 years, annual mammographic surveillance appears adequate following BCS and interval ipsilateral mammograms at 6 and 18 months do not provide additional clinical benefit.
Gunia S R; Merrigan T L; Poulton T B; Mamounas E P
Annals of Surgical Oncology
2012
2012-10
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1245/s10434-012-2578-x" target="_blank" rel="noreferrer noopener">10.1245/s10434-012-2578-x</a>
Dietary Phytochemicals In The Chemoprevention And Treatment Of Hepatocellular Carcinoma: In Vivo Evidence, Molecular Targets, And Clinical Relevance
acid phenethyl ester; altered hepatic foci; black tea; carcinoma; Chemoprevention; dietary; diethylnitrosamine-induced hepatocarcinogenesis; hepatocarcinogenesis; hepatocellular; implanted; liver cancer; liver preneoplastic foci; model; multiorgan carcinogenesis model; nitrosodiethylamine-induced; nude-mice; Oncology; phenobarbital-induced hepatocarcinogenesis; phytochemicals; polyphenols; resistant hepatocyte; treatment
Hepatocellular carcinoma (HCC), one of the most common and lethal cancers, is a growing menace in modern society. Until recently, the majority of detected cases of liver cancer have been found in the developing nations of Asia and Africa; however, its occurrence has significantly increased in the United States. HCC occurs due to several etiologies, such as alcoholism, dietary carcinogens, iron overload, viral hepatitis, as well as several hepatic chronic diseases. In view of the limited treatment options, such as surgery and transplantation, a critical need exists to examine alternative approaches. The use of phytochemicals obtained from dietary sources provides a novel and fascinating preventive and therapeutic approach against HCC. Dietary phytochemicals possess potent antioxidant and anti-inflammatory properties which are extremely critical to combat the significant oxidative stress and inflammation implicated in liver cancer. An impressive number of phytochemicals have shown considerable promise as candidates for the prevention and treatment of HCC. In this article, we systematically review the in vivo pre-clinical evidence documenting the chemopreventive and therapeutic potential of several important dietary phytochemicals in HCC. This review critically examines the molecular mechanisms of the pharmacological effects of the aforementioned animal studies. Clinical and epidemiological studies are also highlighted in this review. Emerging issues such as bioavailability, dose optimization, targeted drug delivery, role of botanical extracts and synergy are also discussed. Finally, current challenges, limitations, future directions, innovative concepts and novel hypotheses for the use of dietary phytochemicals in the chemoprevention and amelioration of human HCC are presented.
Bishayee A; Thoppil R J; Waghray A; Kruse J A; Novotny N A; Darvesh A S
Current Cancer Drug Targets
2012
2012-11
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.2174/156800912803987896" target="_blank" rel="noreferrer noopener">10.2174/156800912803987896</a>
Black Currant Phytoconstituents Exert Chemoprevention Of Diethylnitrosamine-initiated Hepatocarcinogenesis By Suppression Of The Inflammatory Response
Biochemistry & Molecular Biology; cancer-cell proliferation; Chemoprevention; cyclooxygenase-2; cyclooxygenase-2 inhibitors; gamma-glutamyl-transferase; heat-shock proteins; heat-shock proteins; hepatocarcinogenesis; human hepatocellular-carcinoma; Inflammation; liver cancer; molecular chaperones; nf-kappa-b; nuclear factor-B; Oncology; ribes-nigrum; signaling; united-states
Black currant fruits containing high amounts of anthocyanins are known to possess potent antioxidant and anti-inflammatory properties. We have previously reported that anthocyanin-rich black currant skin extract (BCSE) inhibits diethylnitrosamine (DENA)-initiated hepatocarcinogenesis in rats although the underlying mechanisms are not fully understood. Our present study investigates the anti-inflammatory mechanisms of BCSE during DENA rat liver carcinogenesis. Dietary BCSE (100 or 500mg/kg) treatment for 22wk afforded a striking inhibition of DENA-induced hepatic gamma-glutamyl transpeptidase-positive preneoplastic foci in a dose-responsive fashion. There was a significant increase in hepatic expression of heat shock proteins (HSP70 and HSP90), cyclooxygenase-2, and nuclear factor-B (NF-B) in DENA-exposed rat livers. Dietary BCSE dose-dependently abrogated all these elevated inflammatory markers. The possible cardiotoxicity of BCSE was assessed by monitoring cardiac functions using transthoracic echocardiography. BCSE-mediated anti-inflammatory effects during rat liver carcinogenesis have been achieved without any cardiotoxicity. Our results provide convincing evidence, for the very first time, that suppression of the inflammatory cascade through modulation of the NF-B signaling pathway could be implicated, at least in part, in the chemopreventive effects of black currant bioactive phytoconstituents against experimental hepatocarcinogenesis. These results coupled with an excellent safety profile of BCSE support the development of black currant phytochemicals for the chemoprevention of inflammation-driven hepatocellular cancer. (c) 2011 Wiley Periodicals, Inc.
Bishayee A; Thoppil R J; Mandal A; Darvesh A S; Ohanyan V; Meszaros J G; Haznagy-Radnai E; Hohmann J; Bhatia D
Molecular Carcinogenesis
2013
2013-04
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1002/mc.21860" target="_blank" rel="noreferrer noopener">10.1002/mc.21860</a>
Chemoprevention Of Hepatocellular Carcinoma With Anthocyanin-rich Black Currant (ribes Nigrum L.) Extract: In Vitro And In Vivo Evidence
Oncology
Bishayee A; Thoppil R J; Darvesh A S; Bhatia D; Hohmann H
Cancer Research
2011
2011-04
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1158/1538-7445.am2011-4607" target="_blank" rel="noreferrer noopener">10.1158/1538-7445.am2011-4607</a>
Chemopreventive Effect Of A Novel Oleanane Triterpenoid In A Chemically Induced Rodent Model Of Breast Cancer
amooranin; apoptosis; breast cancer; carcinogenesis; carcinoma cell-lines; cddo-methyl ester; cell; Chemoprevention; DMBA; growth arrest; mammary; mice; oleanane triterpenoid; Oncology; prevention; proliferation; rat; tumor-growth
Breast cancer represents one of the most frequently diagnosed cancers and predominant causes of death in women worldwide. The value of preventive therapy to limit the devastating impact of breast cancer is well established. Various plant triterpenoids and their synthetic analogs have shown significant promise as potent chemopreventive agents in breast cancer. The current study was initiated to investigate mechanism-based chemopreventive potential of a novel synthetic oleanane triterpenoid (methyl-25-hydroxy-3-oxoolean-12-en-28-oate, AMR-Me) against 7,12-dimethylbenz(a)anthracene (DMBA)-initiated rat mammary carcinogenesis, an experimental rodent tumor model that closely resembles human mammary cancer. Rats were orally administered with AMR-Me (0.8, 1.2 and 1.6 mg/kg) three times per week for 18 weeks. Following two weeks of AMR-Me treatment, mammary carcinogenesis was initiated by oral administration of DMBA (50 mg/kg body weight). At the end of the study (16 weeks following DMBA exposure), AMR-Me exhibited a striking inhibition of DMBA-induced mammary tumor incidence, total tumor burden, average tumor weight and reversed histopathological alterations without toxicity. AMR-Me dose-dependently suppressed abnormal cell proliferation, induced apoptosis, up-regulated pro-apoptotic protein Bax and down-regulated antiapoptotic protein Bcl-2 in mammary tumors. AMR-Me upregulated the transcriptional levels of Bax, Bad, caspase-3, caspase-7 and poly(ADP-ribose) polymerase and down-regulated Bcl-2. These results clearly demonstrate for the first time that novel triterpenoid AMR-Me exerts chemopreventive efficacy in the classical DMBA model of breast cancer by suppressing abnormal cell proliferation and inducing apoptosis mediated through mitochondrial pro-apoptotic mechanisms. AMR-Me could be developed as a chemopreventive drug to reduce the risk of human breast cancer that remains a devastating disease.
Bishayee A; Mandal A; Thoppil R J; Darvesh A S; Bhatia D
International Journal of Cancer
2013
2013-09
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1002/ijc.28108" target="_blank" rel="noreferrer noopener">10.1002/ijc.28108</a>
Chemopreventive Effect Of Dietary Resveratrol Against Experimental Hepatocellular Carcinogenesis
Oncology
Bishayee A; Dhir N; Jaradat D; Kalman J
Cancer Research
2009
2009-05
Journal Article or Conference Abstract Publication
n/a
The National Surgical Adjuvant Breast And Bowel Project (nsabp)
Obstetrics & Gynecology; Oncology
Mamounas E R; Wickerham D L
Breast Care
2007
2007-12
Journal Article or Conference Abstract Publication
n/a
Neoadjuvant Chemotherapy In Operable Breast Cancer: The Pros
20-year; chemoendocrine therapy; comparing total; follow-up; gene-expression profiles; mastectomy; Obstetrics & Gynecology; Oncology; pathological; preoperative chemotherapy; project protocol b-27; randomized-trial; responses; sentinel lymph-node; surgical adjuvant breast
Mamounas E R
Breast Care
2006
2006-12
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1159/000097887" target="_blank" rel="noreferrer noopener">10.1159/000097887</a>
Tailoring Loco-regional Therapy With Neoadjuvant Chemotherapy: Another Step In The Right Direction
breast; breast-conserving treatment; cancer; carcinoma in-situ; induction chemotherapy; Oncology; preoperative chemotherapy; radiation-therapy; randomized-trial; remission rates; sentinel lymph-node; Surgery; surgical adjuvant
Mamounas E P
Annals of Surgical Oncology
2004
2004-10
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1245/aso.2004.08.908" target="_blank" rel="noreferrer noopener">10.1245/aso.2004.08.908</a>
Surgical Management Of The Breast And Axilla After Neoadjuvant Treatment: The Role Of Sentinel Node Biopsy
cancer; chemotherapy; dissection; Oncology
Mamounas E P
Breast Cancer Research
2009
2009
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1186/bcr2268" target="_blank" rel="noreferrer noopener">10.1186/bcr2268</a>
Surgical Issues In The Breast And Axillary Nodes In Patients Treated With Neoadjuvant Systemic Therapy
biopsy; cancer; chemotherapy; dissection; Oncology; sentinel-node
Mamounas E P
Breast Cancer Research
2007
2007
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1186/bcr1690" target="_blank" rel="noreferrer noopener">10.1186/bcr1690</a>
Age And Lymph Node Status In Breast Cancer: Not A Straightforward Relationship
axillary dissection; biopsy; metastases; morbidity; Oncology; predictors; receptor
Mamounas E P
Journal of Clinical Oncology
2009
2009-06
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1200/jco.2009.22.0509" target="_blank" rel="noreferrer noopener">10.1200/jco.2009.22.0509</a>
Endometrial Cancer Survivors' Assessment Of The Benefits Of Exercise
adherence; breast; Cancer survivors; exercise; Health beliefs; intervention; maintenance; Obesity; Obstetrics & Gynecology; Oncology; outcome expectations; physical-activity; quality-of-life; risk; self-efficacy; women
Lukowski J; Gil K M; Jenison E; Hopkins M; Basen-Engquist K
Gynecologic Oncology
2012
2012-03
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.ygyno.2011.11.002" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2011.11.002</a>
Knowledge Of Cancer Risk Factors
Oncology
Gil K M; Yeropoli S; Fish B; Schnegg L; Savitski J L
Journal of Clinical Oncology
2010
2010-05
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1200/jco.2010.28.15_suppl.1570" target="_blank" rel="noreferrer noopener">10.1200/jco.2010.28.15_suppl.1570</a>
Simultaneous Measurement Of Cancer Specific Quality Of Life And General Health Status In Gynecologic Malignancies
Oncology
Gil K M; Von Gruenigen V E; Frasure H E; Grandon M; Hopkins M P; Jenison E L
Journal of Clinical Oncology
2004
2004-07
Journal Article or Conference Abstract Publication
n/a
Body Weight And Composition Changes In Ovarian Cancer Patients During Adjuvant Chemotherapy
body composition; breast cancer; chemotherapy; gain; Obstetrics & Gynecology; Oncology; ovarian cancer; weight; women
Gil K M; Frasure H E; Hopkins M P; Jenison E L; Von Gruenigen V E
Gynecologic Oncology
2006
2006-10
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.ygyno.2006.03.005" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2006.03.005</a>
Patient Characteristics Influencing Quality Of Life In Gynecologic Cancer
Oncology
Gil K; Frasure H E; Jenison E; Hopkins M; Von Gruenigen V E
Journal of Clinical Oncology
2006
2006-06
Journal Article or Conference Abstract Publication
n/a
Widespread Metastases After Resection Of Noninvasive Thymoma
carcinoma; expression; Oncology; organization histologic classification; relevance; stage; thymic epithelial tumors
Gamboa E O; Sawhney V; Lanoy R S; Haller N A; Powell A T; Hazra S V
Journal of Clinical Oncology
2008
2008-04
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1200/jco.2007.14.5656" target="_blank" rel="noreferrer noopener">10.1200/jco.2007.14.5656</a>
Fournier's Gangrene As A Possible Side Effect Of Bevacizumab Therapy For Resected Colorectal Cancer
Arterial thromboembolism; FGSIS; fluorouracil; leucovorin; Oncology; Vascular endothelial growth factor; Wound-healing complications
Gamboa E O; Rehmus E H; Haller N
Clinical Colorectal Cancer
2010
2010-01
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.3816/CCC.2010.n.008" target="_blank" rel="noreferrer noopener">10.3816/CCC.2010.n.008</a>
Induction Of Drug-metabolizing-enzymes In Human Pancreatic-cancer And Chronic-pancreatitis
chronic pancreatitis; cytochrome P450; cytochrome P450; drug-metabolizing enzymes; ethanol; genetic-polymorphism; glutathione s-transferases; identification; immunocytochemistry; immunohistochemical localization; inducible; liver; Oncology; pancreatic cancer; Pathology; rat; western blotting
Foster J R; Idle J R; Hardwick J P; Bars R; Scott P; Braganza J M
Journal of Pathology
1993
1993-04
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1002/path.1711690412" target="_blank" rel="noreferrer noopener">10.1002/path.1711690412</a>
Millimeter Waves Exposure Set-up For Real-time Monitoring Of Biological Processes At A Molecular Level By Nuclear Magnetic Resonance Spectroscopy
cells; Oncology
Filippelli L; Beneduci A; Cosentino K; Westerman P W; Chidichimo G
Anticancer Research
2008
2008-09
Journal Article or Conference Abstract Publication
n/a
Low Power Millimeter Waves Modify Phospholipid Model Membranes Structure
growth; inhibition; microwaves; Oncology
Filippelli L; Beneduci A; Chidichimo G; Westerman P W; Malmer M; Servello A
Anticancer Research
2004
2004-09
Journal Article or Conference Abstract Publication
n/a
New Insights In The Treatment Of Severe Infections In The Multiple-drug Resistant Situation - Introduction
Oncology; Pharmacology & Pharmacy
File T M
Chemotherapy
2004
2004
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1159/000079815" target="_blank" rel="noreferrer noopener">10.1159/000079815</a>
New Insights In The Treatment By Levofloxacin
adults; amoxicillin-clavulanate; community-acquired pneumonia; fluoroquinolones; high-dose therapy; hong-kong; levofloxacin; multicenter; Oncology; open-label; Pharmacology & Pharmacy; resistance; respiratory infection; safety; streptococcus-pneumoniae; surveillance; trial
File T M
Chemotherapy
2004
2004
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1159/000079819" target="_blank" rel="noreferrer noopener">10.1159/000079819</a>
A 3p Deletion In Small Cell Lung-carcinoma
Genetics & Heredity; Oncology
Falor W H; Wardskinner R; Wegryn S
Cancer Genetics and Cytogenetics
1985
1985
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/0165-4608(85)90012-3" target="_blank" rel="noreferrer noopener">10.1016/0165-4608(85)90012-3</a>
Carcinoma Of The Axillary Breast
axillary breast; breast cancer; ectopic breast; Oncology; Surgery
Evans D M; Guyton D P
Journal of Surgical Oncology
1995
1995-07
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1002/jso.2930590311" target="_blank" rel="noreferrer noopener">10.1002/jso.2930590311</a>
Supportive Care For Patients With Pancreatic Adenocarcinoma: Symptom Control And Nutrition
acute-phase response; cancer-patients; celiac plexus block; eicosapentaenoic acid; endoscopic drainage; Hematology; Oncology; prospective randomized trial; quality-of-life; thoracoscopic splanchnicectomy; total parenteral-nutrition; weight-loss
Ellison N M; Chevlen E; Still C D; Dubagunta S
Hematology-Oncology Clinics of North America
2002
2002-02
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/s0889-8588(01)00006-5" target="_blank" rel="noreferrer noopener">10.1016/s0889-8588(01)00006-5</a>
Biochemical Disease-free Survival Rates Following Definitive Low-dose-rate Prostate Brachytherapy With Dose Escalation To Biologic Target Volumes Identified With Spect/ct Capromab Pendetide
adenocarcinoma; brachytherapy; BTV; cancer; conformal radiation-therapy; dosimetry; external-beam radiation; failure definition; hormonal-therapy; Nuclear Medicine & Medical Imaging; Oncology; ProstaScint; prostascint(r); prostate; Radiology; radiotherapy; recommendations; SPECT/CT; survival
Ellis R J; Zhou H; Kim E Y; Fu P F; Kaminsky D A; Sodee B; Colussi V; Vance W Z; Spirnak J P; Kim C; Resnick M I
Brachytherapy
2007
2007-01
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.brachy.2006.11.002" target="_blank" rel="noreferrer noopener">10.1016/j.brachy.2006.11.002</a>